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We have recently established conditions allowing long-term expansion of epithelial
organoids from human intestine, recapitulating essential features of the in vivo
tissue architecture. Here, we apply this technology to study primary intestinal
organoids of patients who suffer from cystic ﬁbrosis (CF). Forskolin induces a
rapid swelling of wild-type organoids, but not of organoids derived from CFTR-
deﬁcient mice or CF patients. This phenomenon is phenocopied by CFTR-speciﬁc
inhibitors. Function of the common, temperature-sensitive CFTR-F508del mutant is
restored upon incubation at low temperature, as well as by the corrector compounds
VRT-325, Corr-4a, VX-809 and the potentiator VX-770. This relatively simple and
robust assay will facilitate diagnosis, functional studies, drug development as well
as personalized medicine approaches in CF.
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Objective: To evaluate whether assessment of b-adrenergic sweat secretion by
evaporimetry is an accurate and reliable measure of CFTR function.
Methods: We ascertained 2 study cohorts including healthy controls (HC), obligate
heterozygotes (HZ), patients with CFTR-related disease (CFTR-R), pancreatic
sufﬁcient (CFPS) and pancreatic insufﬁcient (CFPI) CF patients in San Diego
and Toronto as surrogates for different levels of CFTR function. b-adrenergic
sweat stimulation was induced by isoproterenol + aminiophylline after inhibition of
cholinergic sweating with atropine and monitored as kg water loss/cm2/hr using an
evaporimeter. Tests were performed 1−4 times for each subject. Sweat [Cl−] was
determined concurrently (Wescor®).
Results: Cholinergic sweat secretion rate did not differ among the groups, but
females sweat less than males (p< 0.0001). In the San Diego cohort b-adrenergic
sweat secretion rate in HZ was 50% of Hc sweat rate (mean; 95%CI: 23; 16−29
vs 51; 46−57) and completely absent in CF patients (−1; −2 − −1); p< 0.0001) and
highly reliable (ICC=0.9; 0.81–0.95). Similar results were obtained in the Toronto
group (table, *p< 0.05 for differences between neighboring groups).
Table 1
Groups (n) Mean (95%CI) HC (5) HZ (5) CFTR-R (10) CFPS (11) CFPI (7)
Sweat Cl− 20 (10−30) 32 (2−61) 46* (36−56) 70* (54−86) 101* (88–113)
Cholinergic sweat secretion 63 (46−80) 67 (46−88) 66 (53−79) 54 (40–67.8) 74 (59−88)
b-adrenergic sweat secretion 63 (43−83) 37* (16−58) 11* (1−21) −0.5* (−2 − 1.1) 1.3* (−0.8 − 3.4)
b-adren/chol Ratio 1.0* (0.8−1.2) 0.5* (0.4−0.7) 0.02 (0.0−0.3) 0 0
Conclusion: b-adrenergic sweat secretion determined by evaporimetry is an accu-
rate, reliable and easy in vivo technique to assess different levels of CFTR function
and may serve as biomarker for diagnosis or as outcome measure in CF.
